Maria Paola Martelli
Overview
Explore the profile of Maria Paola Martelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
3378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marconi G, Petracci E, Lanzarone G, Vetro C, Martelli M, Papayannidis C, et al.
Am J Hematol
. 2025 Jan;
100(4):708-711.
PMID: 39831709
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.
2.
Adorisio S, Fierabracci A, Cham B, Hoang V, Thuy Linh N, Nhung L, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770403
The expression of oncogene zinc-finger protein 217 (ZNF217) has been reported to play a central role in cancer development, resistance, and recurrence. Therefore, targeting ZNF217 has been proposed as a...
3.
Venanzi A, Cardinali V, Perriello V, Albano F, Cimino G, Martino G, et al.
Am J Hematol
. 2024 Aug;
100(1):139-143.
PMID: 39158266
No abstract available.
4.
Pierangeli S, Donnini S, Ciaurro V, Milano F, Cardinali V, Sciabolacci S, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123404
How hematopoietic stem and progenitor cell (HSPC) fate decisions are affected by genetic alterations acquired during AML leukemogenesis is poorly understood and mainly explored in animal models. Here, we study...
5.
Martelli M, Di Renzo N, Curti A, Fracchiolla N, Maurillo L, Caira M, et al.
Leuk Res Rep
. 2024 Jul;
21:100453.
PMID: 39035747
Real-world data on treatment patterns and outcomes of patients with acute myeloid leukemia unfit for intensive chemotherapy are lacking before the advent of precision medicine in this setting. Herein, we...
6.
Venditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Fili C, et al.
Blood Adv
. 2024 Jul;
8(16):4410-4413.
PMID: 38968139
No abstract available.
7.
Marchesini M, Gherli A, Simoncini E, Moron Dalla Tor L, Montanaro A, Thongon N, et al.
Nat Commun
. 2024 Jun;
15(1):4739.
PMID: 38834613
The overexpression of the ecotropic viral integration site-1 gene (EVI1/MECOM) marks the most lethal acute myeloid leukemia (AML) subgroup carrying chromosome 3q26 abnormalities. By taking advantage of the intersectionality of...
8.
Martino G, Cimino G, Caridi M, Perta G, Cardinali V, Sciabolacci S, et al.
Ann Hematol
. 2023 Dec;
103(4):1421.
PMID: 38150113
No abstract available.
9.
Mancusi A, Zorutti F, Ruggeri L, Bonato S, Tricarico S, Zei T, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003295
Blinatumomab alone or with donor leukocyte infusions (DLI) has been used after allogeneic hematopoietic stem cell transplantation (HSCT) as a salvage therapy in relapsing patients with CD19 hematological malignancies. It...
10.
Martino G, Cimino G, Caridi M, Perta G, Cardinali V, Sciabolacci S, et al.
Ann Hematol
. 2023 Jul;
102(10):2969-2971.
PMID: 37481474
No abstract available.